IRenaudin
TL2 Member · Lausanne, CH
UK-based. Mostly the access and pricing categories.
Joined 5 February 2025 · last posted 2d · groups: regional-uk
85 posts, newest first. Showing up to 150.
-
GLP-1 receptor distribution: central and peripheral Replied, post #98 · Pharmacology › Receptor biology · 26 Jul 2026 · 1 like Central versus peripheral action: GLP-1 agonism works through both central nervous system effects (appetite) and peripheral effects (gastric motility, insulin). The…
-
An 18-month record including the parts that went badly Replied, post #78 · Outcomes › Progress reports · 23 Jul 2026 · 0 likes I read post #76 twice before replying, because I had assumed the opposite. Exercise volume changes: increasing exercise intensity or duration can mask weight loss…
-
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #20 · Compounds › Oral incretins · 23 Jul 2026 · 1 like Coming back to post #18, because the follow-up matters more than the original answer. PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple…
-
Specificity, linearity, accuracy, precision, range, robustness — with real criteria Replied, post #46 · Analytics › Method validation · 20 Jul 2026 · 6 likes This follows post #43 rather than contradicting it. Robustness: the method gives consistent results when minor parameters vary. Tested by deliberately varying pH,…
-
Private prescribing in the UK: what is actually involved Replied, post #65 · Regional › UK & Ireland · 15 Jul 2026 · 2 likes Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant…
-
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #2 · Compounds › Retatrutide · 11 Jul 2026 · 29 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
-
Follow-up: Reading an interaction checker output critically Replied, post #35 · Practice › Interactions · 7 Jul 2026 · 1 like For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
How much context is too much context in a first post? Replied, post #20 · Start Here › How to Ask · 6 Jul 2026 · 13 likes Worth separating two things that post #16 runs together. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather…
-
NHS criteria and how they are applied in practice Replied, post #15 · Regional › UK & Ireland · 30 Jun 2026 · 24 likes Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #100 · Evidence › Journal club · 28 Jun 2026 · 0 likes On post #96 — agreed on the reasoning, with one qualification. SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes. The first outcome trial…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #110 · Practice › Reconstitution · 15 Jun 2026 · 5 likes A vial that will not fully dissolve: check in order: is the diluent genuinely room temperature (some preservatives crystallise in cold), is the vial being warmed gently…
-
What consumer-accessible tests can and cannot determine — a second dataset Started this topic · Analytics › Home & field testing · 12 Jun 2026 · 17 likes What consumer-accessible tests can and cannot determine — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below.…
-
Micronutrient adequacy at low total intake Replied, post #65 · Nutrition & Training › Protein & intake · 11 Jun 2026 · 0 likes Protein sources: animal sources (meat, fish, eggs, dairy) are denser and easier to hit targets with. Plant sources require higher volume. Neither is nutritionally…
-
Request: a per-category review queue Replied, post #29 · Meta › Feature requests · 10 Jun 2026 · 1 like On post #25 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…
-
Prescription portability between countries Replied, post #54 · Access › International · 5 Jun 2026 · 8 likes Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more…
-
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #50 · Analytics › HPLC & UHPLC · 29 May 2026 · 2 likes Detection wavelength: 214 nm detects the peptide bond and is relatively insensitive to composition. 280 nm detects aromatic residues and is strongly…
-
Clearance pathways and what renal impairment changes Replied, post #16 · Pharmacology › Pharmacokinetics · 26 May 2026 · 5 likes Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady…
-
What to include when your question involves a chromatogram — one year on Replied, post #8 · Start Here › How to Ask · 17 May 2026 · 15 likes Worth separating two things that post #4 runs together. Chromatogram questions: describe the method first. Column type, gradient, wavelength, detection method.…
-
Forced degradation studies: designing one that is informative Replied, post #56 · Analytics › Method validation · 15 May 2026 · 29 likes Range: the concentration range over which the method has been validated. Going outside the validated range is going outside the method's demonstrated performance.
-
Reading a trial's population section before its results Replied, post #22 · Evidence › Trials · 15 May 2026 · 25 likes The estimand: what the trial set out to estimate. Two trials can be identical in structure but estimate different things by using different handling rules for people…
-
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #73 · Evidence › Trials · 5 May 2026 · 22 likes Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters.…
-
Foaming during reconstitution and whether it matters — the long version Replied, post #113 · Practice › Reconstitution · 26 Apr 2026 · 16 likes Choosing a concentration on purpose rather than by accident: starting with "I want to draw 0.5 mL per dose" and working backward to the required concentration is more…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #46 · Evidence › Journal club · 24 Apr 2026 · 2 likes This follows post #43 rather than contradicting it. Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question?…
-
List price versus negotiated price versus what you pay Replied, post #94 · Access › Pricing · 16 Apr 2026 · 6 likes Picking up post #91: that is the part I would want checked first. Pharmacy acquisition cost: a pharmacy pays less than the patient pays, even at insurance rates. That…
-
List price versus negotiated price versus what you pay Replied, post #71 · Access › Pricing · 14 Apr 2026 · 7 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Second pass at: Which categories are strict and which are relaxed, honestly Replied, post #32 · Start Here › Welcome · 29 Mar 2026 · 0 likes This follows post #29 rather than contradicting it. The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the…
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #118 · Access › Pricing · 17 Mar 2026 · 2 likes Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented…
-
Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #27 · Compounds › Cagrilintide & amylin analogues · 25 Feb 2026 · 2 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Second pass at: Temperature logging at home: what is worth the effort Replied, post #3 · Practice › Storage & stability · 17 Feb 2026 · 0 likes This follows post #2 rather than contradicting it. I want to gently push back on the reply above about storage extrapolation. The advice is sound and the confidence is…
-
Pinch or no pinch, and how needle length changes the answer — the long version Replied, post #17 · Practice › Administration · 7 Feb 2026 · 0 likes Cold solution and stinging: warming the vial in your hands for a minute before injection reduces the stinging sensation substantially. This is the simplest thing to try…
-
Storing lyophilised material long term: what governs the shelf life Replied, post #48 · Practice › Storage & stability · 2 Feb 2026 · 0 likes Temperature excursions: if a vial sat at room temperature for a time, the question is whether the excursion was long enough to cause damage. Hours at room temperature…
-
Pen mechanics when the cartridge is nearly empty — does this still hold? Replied, post #46 · Devices › Pens & autoinjectors · 19 Jan 2026 · 7 likes I read post #44 twice before replying, because I had assumed the opposite. Storage after first use: most pens can be stored at room temperature after first use, even if…
-
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #10 · Analytics › Mass spectrometry · 16 Jan 2026 · 14 likes Coming back to post #8, because the follow-up matters more than the original answer. Calibration matters: a high-resolution instrument out of calibration can report…
-
Aggregates and why a purity assay may miss them entirely Replied, post #56 · Analytics › Impurities & related substances · 7 Jan 2026 · 18 likes Worth separating two things that post #52 runs together. Aggregates: multiples of the monomer mass. May not elute at all under a standard reversed-phase method. A…
-
A partial dose because the pen emptied mid-injection Started this topic · Practice › Administration · 6 Jan 2026 · 13 likes A partial dose because the pen emptied mid-injection Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the…
-
Request: a diff view for wiki revisions — the long version Replied, post #90 · Meta › Feature requests · 27 Dec 2025 · 9 likes Feature scope: some requests are for the site itself (search, filtering, navigation). Some are for the documentation (new topics, different formats). Scope helps…
-
Personal import allowances, compared Replied, post #6 · Access › International · 20 Dec 2025 · 1 like Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is…
-
The decimal-point error, and the habit that catches it Replied, post #96 · Practice › Reconstitution · 17 Dec 2025 · 9 likes On post #92 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
Second pass at: What "verified" means on our vendor pages, stated narrowly Replied, post #45 · Sourcing › Vendor reports · 13 Dec 2025 · 6 likes On post #41 — agreed on the reasoning, with one qualification. Structured report format: compound, lot, independent testing service, method as reported, result, and the…
-
Introducing myself: pharmacist, sceptic, reluctant participant Started this topic · Lounge › Introductions · 10 Dec 2025 · 30 likes Introducing myself: pharmacist, sceptic, reluctant participant Writing it up because I had to work it out twice and would rather nobody else did. Lower-stakes topic,…
-
[2026 update] Are there stupid questions here? A staff answer, at length Replied, post #9 · Start Here › Welcome · 21 Nov 2025 · 11 likes post #8 answers the question as asked. The question underneath it is different. Your introduction is well framed. You have given enough context that people can actually…
-
High-resolution MS on aggregates and what it can see Replied, post #121 · Analytics › Mass spectrometry · 15 Nov 2025 · 4 likes Sample matrix effects: if a sample is dissolved in a complex matrix, other compounds in the matrix can suppress the peptide signal. Clean samples give higher…
-
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #48 · Wellbeing › Mental health · 10 Nov 2025 · 29 likes Support and community: some people process weight change through community (online or in-person). Others prefer privacy. Knowing what you need and seeking it…
-
New subcategory: rationale and scope Replied, post #133 · Meta › Announcements · 27 Oct 2025 · 1 like RSS: if you prefer to receive announcements by feed rather than visiting the site, RSS is available for this subcategory.
-
Second pass at: Robustness: the parameters worth deliberately varying Replied, post #21 · Analytics › Method validation · 24 Oct 2025 · 25 likes Linearity: the detector response is proportional to compound concentration across the working range. Demonstrated by running standards at multiple concentrations and…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #109 · Start Here › Welcome · 22 Oct 2025 · 3 likes This follows post #106 rather than contradicting it. Your introduction is well framed. You have given enough context that people can actually answer. That is rarer than…
-
Payment mechanics and the recovery options that do not exist Replied, post #65 · Sourcing › Payments · 21 Oct 2025 · 15 likes Refund policy before ordering: ask what the policy is if you receive damaged material or if the order is incorrect. Get it in writing or screenshot it.
-
The headache that turns out to be dehydration Replied, post #29 · Nutrition & Training › Hydration & electrolytes · 20 Oct 2025 · 5 likes The very ordinary causes of week-two malaise: inadequate hydration, low sodium intake, too-rapid calorie deficit, and inadequate sleep are more common causes of fatigue…
-
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #96 · Evidence › Preprints · 3 Oct 2025 · 4 likes I read post #94 twice before replying, because I had assumed the opposite. Peer review as a filter: published papers have survived a review process that rejects many…
-
Dose numbers across compounds are not on the same scale Replied, post #2 · Practice › Dosing & titration · 14 Sep 2025 · 32 likes Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that…
-
Titles that describe the question, not the situation — what changed since Replied, post #11 · Start Here › How to Ask · 12 Sep 2025 · 0 likes I read post #9 twice before replying, because I had assumed the opposite. Two things before anyone answers the substance. First, the context in the first post is clear…
-
Persistent vomiting and the threshold for seeking help Replied, post #31 · Safety › Adverse events · 9 Sep 2025 · 30 likes I read post #29 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say…
-
A calculator that gives a right answer to the wrong question — does this still hold? Replied, post #10 · Data & Tools › Calculators · 7 Sep 2025 · 16 likes post #9 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather than…
-
Sample size calculations, read backwards from the published number Started this topic · Evidence › Trials · 4 Sep 2025 · 2 likes Sample size calculations, read backwards from the published number Writing it up because I had to work it out twice and would rather nobody else did. Session topic:…
-
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one… Replied, post #2 · Compounds › Oral incretins · 1 Sep 2025 · 30 likes PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because…
-
Tracking that stops updating and then resumes Replied, post #21 · Sourcing › Logistics · 26 Aug 2025 · 0 likes Reshipment after seizure: if a parcel is seized, some suppliers will reship; others will not. That is a supplier choice and should be understood before ordering in a…
-
How to research a compound with no human data without deceiving yourself Replied, post #22 · Compounds › Other compounds · 31 Jul 2025 · 3 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #162 · Practice › Reconstitution · 12 Jul 2025 · 4 likes A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL gives roughly 2.5 mg/mL. The arithmetic is the same; the…
-
Lipase elevation without symptoms: the interpretation problem Started this topic · Clinical › Bloodwork · 1 Jun 2025 · 44 likes Lipase elevation without symptoms: the interpretation problem Writing it up because I had to work it out twice and would rather nobody else did. Asking about a…
-
Second pass at: Retatrutide mass and identity: what a report should show Replied, post #55 · Compounds › Retatrutide · 29 May 2025 · 5 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
-
Pre-registering a personal experiment, seriously Replied, post #41 · Research Methods › N-of-1 designs · 29 May 2025 · 15 likes On post #37 — agreed on the reasoning, with one qualification. When to run an n-of-1: this design works when you want to know whether a treatment works for you, not…
-
Coming back to: Getting a referral rather than a refusal Replied, post #7 · Clinical › Prescriber conversations · 27 May 2025 · 17 likes What to bring: copies of relevant lab results, pharmacy records (to confirm doses actually taken), and records of any adverse effects you have experienced with other…
-
Forced degradation studies: designing one that is informative — does this still hold? Replied, post #4 · Analytics › Method validation · 27 May 2025 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Second pass at: Reading a combination trial: attributing effect to components Replied, post #16 · Compounds › Cagrilintide & amylin analogues · 15 May 2025 · 18 likes Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a…
-
Adjudicated events and why the definition matters — the long version Replied, post #137 · Evidence › Trials · 5 May 2025 · 13 likes Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the…
-
Distinguishing a deletion sequence by mass alone — the long version Replied, post #17 · Analytics › Mass spectrometry · 28 Apr 2025 · 3 likes Coming back to post #15, because the follow-up matters more than the original answer. Desalting before analysis: some samples need desalting to remove salts that…
-
Review: a draft on reconstitution arithmetic, with objections Replied, post #115 · Documentation › Doc review · 20 Apr 2025 · 0 likes I read post #113 twice before replying, because I had assumed the opposite. Evidence synthesis requests: if you think a page should summarise the state of evidence on a…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #53 · Evidence › Journal club · 19 Apr 2025 · 0 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
-
A report I filed that turned out to be wrong, and the correction Replied, post #19 · Sourcing › Vendor reports · 19 Apr 2025 · 3 likes Temporal patterns: if results from a supplier were good two years ago but have deteriorated recently, that is information. If they have been consistent over years, that…
-
An emergency department visit, described afterwards Replied, post #12 · Safety › Adverse events · 17 Apr 2025 · 0 likes Reporting to regulatory agencies: if you have had a serious event, reporting it to the regulatory agency in your country can help with signal detection across the…
-
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #16 · Compounds › Oral incretins · 10 Apr 2025 · 7 likes Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that…
-
Telehealth prescribing models in the US Replied, post #73 · Regional › North America · 20 Mar 2025 · 31 likes Telehealth prescribing: widespread in the US and varying in quality. Models without a clinician reviewing measurements and history are not recommended by this community.
-
Coming back to: Sample size calculations, read backwards from the published number Replied, post #2 · Evidence › Trials · 13 Mar 2025 · 19 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #5 · Compounds › Oral incretins · 11 Mar 2025 · 12 likes Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of…
-
Validating a method you did not develop — does this still hold? Replied, post #85 · Analytics › Method validation · 7 Mar 2025 · 27 likes System suitability: injections run at the start of a batch to establish that the instrument and column are performing. Acceptance criteria typically include replicate…
-
Revisiting: German, French and Dutch differences, compared Started this topic · Regional › European Union · 1 Mar 2025 · 0 likes Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question…
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #25 · Analytics › COA interpretation · 25 Feb 2025 · 0 likes When method identifiers are missing: "reversed-phase HPLC" is less specific than "reversed-phase HPLC at 214 nm on a C18 column with a 10 to 40% acetonitrile gradient…
-
Deamidation and the close-eluting pair it produces Started this topic · Analytics › Impurities & related substances · 20 Feb 2025 · 27 likes Deamidation and the close-eluting pair it produces Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #79 · Evidence › Meta-analyses · 9 Feb 2025 · 31 likes Why forest plots are more informative than pooled numbers: they show the variation across studies, which tells you whether the effect is consistent or heterogeneous. A…
-
Fixed versus detachable needles: the trade-offs Replied, post #113 · Devices › Syringes & needles · 15 Jan 2025 · 6 likes post #112 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
What we do not know about retatrutide, listed explicitly Replied, post #40 · Compounds › Retatrutide · 1 Jan 2025 · 27 likes Worth separating two things that post #36 runs together. Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and…
-
Second pass at: How to research a compound with no human data without deceiving yourself Replied, post #3 · Compounds › Other compounds · 6 Dec 2024 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #73 · Clinical › Special populations · 25 Nov 2024 · 22 likes Renal impairment: the compounds are cleared renally to some degree. Dose adjustments might be needed in severe renal impairment. Consulting with a clinician familiar…
-
Transit times by route, from a logged dataset — the long version Replied, post #27 · Sourcing › Logistics · 7 Nov 2024 · 3 likes post #26 answers the question as asked. The question underneath it is different. Declaring contents accurately: declaring accurately reduces intervention risk. A…
-
Reporting a discrepancy without making an allegation Replied, post #21 · Sourcing › Vendor reports · 10 Aug 2024 · 1 like post #20 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather…